๐Ÿ”ฌDeep Research

GDRX โ€” GoodRx Holdings ยท catalysts, narrative & risks

ยท14 sourcesGDRX forecast โ†’

GoodRx Holdings (GDRX) โ€” Research Brief as of 2026-10-27

Recent Catalysts (last ~1โ€“3 months)

Q2 2026 earnings (early August 2026). GoodRx reported Q2 2026 results in early August (Aug 5 per [4], Aug 6 per [8]). Top-line results beat consensus: revenue of $200.41M (down 1.3% YoY but above the ~$193.23M consensus estimate) and EPS of $0.08, meeting estimates [4]. Segment growth was strong โ€” Pharma Direct revenue up 76% YoY and subscriptions up 39% YoY โ€” prompting the company to raise full-year revenue and EBITDA guidance [8].


AI-assisted research from the K3vl4r desk โ€” not personalized investment advice. More research โ†’